Evidence map›Paper›PMID 29145892›Full record

ArticleBMC medicine2017

Association between plasma phospholipid saturated fatty acids and metabolic markers of lipid, hepatic, inflammation and glycaemic pathways in eight European countries: a cross-sectional analysis in the EPIC-InterAct study.

Ju-Sheng Zheng, Stephen J Sharp, Fumiaki Imamura, Albert Koulman, Matthias B Schulze, Zheng Ye, Jules Griffin, Marcela Guevara, José María Huerta, Janine Kröger and 35 more

Open access · goldAbstract read
In one paragraph

Article in BMC medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed, 4 pooled it
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 4 syntheses or guidelines pooled it, 72 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

45 authors at 20 institutions in 9 countries.

Ju-Sheng ZhengMRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Box 285, Institute of Metabolic Science, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK. jusheng.zheng@mrc-epid.cam.ac.uk.ORCID 0000-0001-6560-4890
Stephen J SharpMRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Box 285, Institute of Metabolic Science, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK.
Fumiaki ImamuraMRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Box 285, Institute of Metabolic Science, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK.
Albert KoulmanMRC Elsie Widdowson Laboratory, Cambridge, UK.
Matthias B SchulzeDepartment of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
Zheng YeMRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Box 285, Institute of Metabolic Science, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK.
Jules GriffinDepartment of Biochemistry, University of Cambridge, Cambridge, UK.
Marcela GuevaraNavarra Public Health Institute (ISPN), Pamplona, Spain.
José María HuertaCIBER Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Janine KrögerDepartment of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
Ivonne SluijsUniversity Medical Center Utrecht, Utrecht, The Netherlands.
Antonio AgudoUnit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
Aurelio BarricarteNavarra Public Health Institute (ISPN), Pamplona, Spain.
Heiner BoeingDepartment of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
Sandra Colorado-YoharNavarra Institute for Health Research (ldiSNA), Pamplona, Spain.
Courtney DowINSERM U1018, Center for Research in Epidemiology and Population Health, Villejuif, France.
Miren DorronsoroPublic Health Division of Gipuzkoa, San Sebastian, Spain.
Pia T DinesenDepartment of Cardiology, Aalborg University Hospital, Aalborg, Denmark.
Guy FagherazziINSERM U1018, Center for Research in Epidemiology and Population Health, Villejuif, France.
Paul W FranksLund University, Malmö, Sweden.
Edith J M FeskensWageningen University, Wageningen, Netherlands.
Tilman KühnGerman Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg, Germany.
Verena Andrea KatzkeGerman Cancer Research Center (DKFZ), Division of Cancer Epidemiology, Heidelberg, Germany.
Timothy J KeyCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
Kay-Tee KhawDepartment of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Maria Santucci de MagistrisA.O.U. Federico II, Naples, Italy.
Francesca Romana ManciniINSERM U1018, Center for Research in Epidemiology and Population Health, Villejuif, France.
Elena Molina-PortilloCIBER Epidemiology and Public Health (CIBERESP), Madrid, Spain.
Peter M NilssonLund University, Malmö, Sweden.
Anja OlsenDanish Cancer Society Research Center, Copenhagen, Denmark.
Kim OvervadDepartment of Cardiology, Aalborg University Hospital, Aalborg, Denmark.
Domenico PalliCancer Research and Prevention Institute (ISPO), Florence, Italy.
Jose Ramón QuirósPublic Health Directorate, Asturias, Spain.
Olov RolandssonUmeå University, Umeå, Sweden.
Fulvio RicceriDepartment of Clinical and Biological Sciences, University of Turin, Turin, Italy.
Annemieke M W SpijkermanNational Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
Nadia SlimaniInternational Agency for Research on Cancer, Lyon, France.
Giovanna TagliabueFondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Anne TjonnelandDanish Cancer Society Research Center, Copenhagen, Denmark.
Rosario TuminoCancer Registry and Histopathology Department, "Civic M.P. Arezzo" Hospital, ASP, Ragusa, Italy.
Yvonne T van der SchouwUniversity Medical Center Utrecht, Utrecht, The Netherlands.
Claudia LangenbergMRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Box 285, Institute of Metabolic Science, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK.
Elio RiboliSchool of Public Health, Imperial College London, London, UK.
Nita G ForouhiMRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Box 285, Institute of Metabolic Science, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK. Nita.Forouhi@mrc-epid.cam.ac.uk.
Nicholas J WarehamMRC Epidemiology Unit, University of Cambridge School of Clinical Medicine, Box 285, Institute of Metabolic Science, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK.
University of Cambridge · GBGerman Institute of Human Nutrition · DEInserm · FRDanish Cancer Society · DKGerman Cancer Research Center · DEInstituto de Salud Pública de Navarra · ESLund University · SEUniversity Medical Center Utrecht · NLAalborg University Hospital · DKAarhus University · DKAzienda Usl 8 Arezzo · ITCentre international de recherche sur le cancer · FRFederico II University Hospital · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITGobierno del Principado de Asturias · ESImperial College London · GBInstitut d'Investigació Biomédica de Bellvitge · ESInstituto Murciano de Investigación Biosanitaria · ESMRC Human Nutrition Research · GBNational Institute for Public Health and the Environment · NL

Funding

Cancer Research UK 14136Cancer Research UK 16491Cancer Research UK C570/A16491Cancer Research UK C8221/A19170Medical Research Council G0401527Medical Research Council G1000143Medical Research Council MC_EX_MR/L100002/1Medical Research Council MC_PC_13030Medical Research Council MC_UP_A090_1006Medical Research Council MC_UU_12015/1Medical Research Council MC_UU_12015/5Medical Research Council MR/M012190/1Medical Research Council MR/N003284/1Medical Research Council MR/P011705/1Medical Research Council MR/P01836X/1World Health Organization 001
6 · The paper itself

Abstract

backgroundAccumulating evidence suggests that individual circulating saturated fatty acids (SFAs) are heterogeneous in their associations with cardio-metabolic diseases, but evidence about associations of SFAs with metabolic markers of different pathogenic pathways is limited. We aimed to examine the associations between plasma phospholipid SFAs and the metabolic markers of lipid, hepatic, glycaemic and inflammation pathways.

methodsWe measured nine individual plasma phospholipid SFAs and derived three SFA groups (odd-chain: C15:0 + C17:0, even-chain: C14:0 + C16:0 + C18:0, and very-long-chain: C20:0 + C22:0 + C23:0 + C24:0) in individuals from the subcohort of the European Prospective Investigation into Cancer and Nutrition (EPIC)-InterAct case-cohort study across eight European countries. Using linear regression in 15,919 subcohort members, adjusted for potential confounders and corrected for multiple testing, we examined cross-sectional associations of SFAs with 13 metabolic markers. Multiplicative interactions of the three SFA groups with pre-specified factors, including body mass index (BMI) and alcohol consumption, were tested.

resultsHigher levels of odd-chain SFA group were associated with lower levels of major lipids (total cholesterol (TC), triglycerides, apolipoprotein A-1 (ApoA1), apolipoprotein B (ApoB)) and hepatic markers (alanine transaminase (ALT), aspartate transaminase (AST), gamma-glutamyl transferase (GGT)). Higher even-chain SFA group levels were associated with higher levels of low-density lipoprotein cholesterol (LDL-C), TC/high-density lipoprotein cholesterol (HDL-C) ratio, triglycerides, ApoB, ApoB/A1 ratio, ALT, AST, GGT and CRP, and lower levels of HDL-C and ApoA1. Very-long-chain SFA group levels showed inverse associations with triglycerides, ApoA1 and GGT, and positive associations with TC, LDL-C, TC/HDL-C, ApoB and ApoB/A1. Associations were generally stronger at higher levels of BMI or alcohol consumption.

conclusionsSubtypes of SFAs are associated in a differential way with metabolic markers of lipid metabolism, liver function and chronic inflammation, suggesting that odd-chain SFAs are associated with lower metabolic risk and even-chain SFAs with adverse metabolic risk, whereas mixed findings were obtained for very-long-chain SFAs. The clinical and biochemical implications of these findings may vary by adiposity and alcohol intake.

Indexed as

AdultAgedBiomarkersBlood GlucoseBody Mass IndexCholesterol, HDLCholesterol, LDLCross-Sectional StudiesDietary FatsEuropeFatty AcidsFemaleHumansInflammationLipidsMaleBiomarkersBlood GlucoseCholesterol, HDLCholesterol, LDLDietary FatsFatty AcidsLipidsTriglyceridesEven-chainGlycaemicHepaticInflammationLipidsMetabolic markersOdd-chainSaturated fatty acidsVery-long-chain

Identifiers

PMID29145892
PMCPMC5691386
OpenAlexW2770962941

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.